Stay updated with breaking news from பாஸ்கல் நீகெண். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Helix BioPharma Corp.: Helix Biopharma Corp. Responds to Market Activity RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares. About Helix BioPharma Corp. Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Helix is a biopharmaceutical company developing unique therapies in the field of immuno-oncology, for the prevention and treatment of cancer, based on its proprietary technology platform DOS47. Helix is currently listed on the TSX under the symbol HBP . For more information: https://www.helixb ....
Tetra Bio-Pharma Files New Drug Submission for REDUVO in Canada Tetra meets another key milestone before the end of the year OTTAWA, ON / ACCESSWIRE / December 30, 2020 / Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the New Drug Submission (NDS) for the Dronabinol Soft Gel capsules, has been filed with Health Canada. If successful, it will provide Tetra with its first Drug Identification Number (DIN) for a THC-based prescription drug. The new drug name, REDUVO, is pending approval by Health Canada. REDUVO will allow Tetra to establish a revenue stream based on a synthetic cannabinoid drug for major markets in Chemotherapy-induced Nausea and Vomiting (CINV). The addressable market is estimated to be $80M CDN by 2022 ....
Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Helix BioPharma Corp. Closes Private Placement RICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp. (TSX:HBP) ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000. The terms of the placement are for the purchase of units at $0.50 per unit. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.70 and have an expiry of five years from the date of issuance. Helix intends to use the net proceeds of the private placement for working capital and research and development activities. ....